Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies
Anastasia Gkiala,1 Sotiria Palioura2 1National and Kapodistrian University of Athens School of Medicine, Athens, Greece; 2Athens Vision Eye Institute, Athens, GreeceCorrespondence: Sotiria PaliouraAthens Vision Eye Institute, 328-330 Syngrou Ave., Kallithea, Athens 17673, GreeceTel +30 698 580 2355E...
Enregistré dans:
| Auteurs principaux: | Gkiala A, Palioura S |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/96d740eef50a4661b616ed467f3e7953 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
par: Wolfram Samlowski, et autres
Publié: (2021) -
BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
par: Stefanie Hoyer, et autres
Publié: (2021) -
Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
par: Sandip Ganguly, et autres
Publié: (2021) -
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
par: Zoe Apalla, et autres
Publié: (2021) -
Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
par: Marc-Oliver Grimm, et autres
Publié: (2021)